Company Overview
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.07.
Recent Developments
- Dec 2025 Revenue of $324.39K (+366.7% YoY); net profit $-3.98M.
- Trailing 12 Months Year-on-year growth — revenue +46.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 46.90% |
Stock Price Performance
| 1 Year: | -50.29% |
| 6 Months: | -17.92% |
| 3 Months: | -24.35% |
| 1 Month: | +5.97% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)44.80 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 67.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GDTC CytoMed Therapeutics Limited PHARMA | 0.87 | -3.22 | $10.29M | 0.00% | -58.30% | -50.28% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 69.50K | 324.39K |
| Cost of Revenue | - | 0 | 0 | 17.12K | 67.99K |
| Gross Profit | - | 0 | 0 | 52.38K | 256.39K |
| Operating Expenses | - | 1.86M | 3.84M | 3.18M | 4.50M |
| Operating Income | - | -1.86M | -3.84M | -3.13M | -4.24M |
| EBITDA | - | -2.61M | -3.70M | -2.17M | -3.57M |
| Interest Expense | - | 125.17K | 51.28K | 20.31K | 20.91K |
| Pretax Income | - | -3.13M | -4.13M | -2.52M | -4.00M |
| Tax Provision | - | 1.64K | 653 | 0 | 0 |
| Net Income | - | -3.13M | -4.13M | -2.52M | -3.98M |
| Diluted EPS | -0.19 | -0.29 | -0.39 | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 5.23M | 12.37M | 10.07M | 7.98M |
| Current Assets | - | 2.49M | 10.10M | 6.00M | 3.66M |
| Cash & Equivalents | - | 1.58M | 9.00M | 4.97M | 2.10M |
| Inventory | - | - | - | - | - |
| Receivables | - | - | 0 | 18.78K | 103.86K |
| Total Liabilities | - | 4.64M | 1.12M | 1.02M | 1.13M |
| Current Liabilities | - | 4.17M | 716.94K | 606.62K | 709.17K |
| Long Term Debt | - | 468.83K | 407.77K | 394.31K | 368.66K |
| Total Debt | - | 4.22M | 448.02K | 463.25K | 482.56K |
| Total Equity | - | 586.98K | 11.25M | 8.97M | 6.54M |
| Shares Outstanding | - | 10.94M | 11.53M | 11.54M | 11.83M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -1.40M | -3.53M | -2.71M | -3.70M |
| Investing Cash Flow | - | -473.31K | -2.73M | 1.13M | 929.28K |
| Financing Cash Flow | - | 968.72K | 10.92M | -64.89K | 208.65K |
| Capital Expenditure | - | -473.80K | -58.30K | -1.49M | -703.13K |
| Free Cash Flow | - | -1.87M | -3.59M | -4.20M | -4.40M |
| Net Change in Cash | - | -903.00K | 4.66M | -1.65M | -2.56M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 75.4% | 79.0% |
| Operating Margin % | - | - | - | -4,504.3% | -1,307.6% |
| Net Margin % | - | - | - | -3,621.1% | -1,227.1% |
| ROE % | - | -533.4% | -36.8% | -28.1% | -60.8% |
| ROCE % | - | -174.8% | -33.0% | -33.1% | -58.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Axiom Investment Management LLC | 0.06% | 7.03K | $6.89K |
| 2 | UBS Group AG | 0.04% | 4.83K | $4.73K |
| 3 | Osaic Holdings Inc. | - | 21 | $20 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GDTC
CytoMed Therapeutics Limited Ordinary Shares (NASDAQ: GDTC) Stock Price, News & Analysis - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE16cUpzX1hxYmhfYnJtWnNEbmtZaU5jdDgyZ0xXeF82Y1JIaVVDcTZ5RnZzbWNfMS1YdU1UcXBMT2VJUzNjaHU0ejFuWVZGc3dwUmstRWV3?oc=5" target="_blank">CytoMed Therapeutics Limited Ordinary Shares (NASDA…
CytoMed Therapeutics (GDTC) chair discloses 24.3% share stake - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPcmM0ekdzMVV2MTIwUWo3Ym9WMFZWeEZKbllhS2phVmVHODFIWTV0Z0tpd2hIMlhNV2pCVVh5c0cyTTU2VUoyS0tkTFlKZmw0ZzRxemZPRHRuRTdNNGQzdFpBa1ZteFp3WWpfV0ZWRkx4YzAySHJCNmZDb0l5VThabFQwWnFiZjdMc1l1ek…
Insider Purchase: Director at $GDTC Buys 112,000 Shares - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPeVpXWDBDb3hBaHdUbl85dnFSaHZPNnFqazh5NmN0TjgxRVg2a2lEcW51MlV6cDYxMndpTkFjYlJtb0tXZFV6dnA5cGNFR19za2FEcFA2amVrSkJIQ1ByMHAwWGZiU0tfZmVRLUZoUnU4eGVOYXB0b2diajRLbVpfSmVRMFpHLUdoRVE2cE…
CytoMed Therapeutics' US$1.7m Market Cap Fall Books Insider Losses - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxPRjJEaEc2dE52LWZpMkMwVVYxM1pFVDdxRTVuUzlmc0E2aklYZ2h5T0xDcXA0UjFRWktEWDRMTlNxR3ZIZzZuNDI0VUZxbGs0Zy1MQndRTGZZMzVKanNqUXdiei1CTHZ1NFNIU3k5Y2MxV1hTcVdEM05MSnpGdURfdnc4VlRyT0QxUjJCdX…
GDTC - CytoMed Therapeutics Ltd Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1EZVhqYVI5NzFfYXJpcGtRRndlWGFlYVZ6dzN1REgyYWNHaVRGSnl2eW5QVmZpS2tzMG5YOEJfcUJnMHBXcXc?oc=5" target="_blank">GDTC - CytoMed Therapeutics Ltd Stock Price and Quote</a> <fo…
CytoMed Therapeutics (GDTC) insider discloses two ordinary share dispositions - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNYks3d2lPRDNuejYwbUxTQnhzT0d6QlREbXBTUjk2TkllZHVYNW5DWnhLUDNaclNpMFJZaWNhUFdiV0JsYzQzdzd1bEU5R085clpsd0JmMjBoN2NhdHI1djgxMTdvUzk2RTZ1MVUxNTBWZ1dUOS1XUVRNOER5YWx2dF9WczVRZ3lCNU1kLX…
GDTC — Frequently Asked Questions
What is the current share price of CytoMed Therapeutics Limited (GDTC)?
As of 2026-09-19 21:16 PDT, CytoMed Therapeutics Limited (GDTC) trades at $0.87 on NasdaqCM. Its 52-week range is $0.72 to $2.69.
What is the market capitalisation of GDTC?
CytoMed Therapeutics Limited (GDTC) has a market capitalisation of $10.29M on NasdaqCM.
What is the P/E ratio of GDTC?
GDTC trades at a trailing price-to-earnings (P/E) ratio of -3.22. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.26.
What is the return on equity (ROE) of GDTC?
GDTC has a return on equity (ROE) of -50.28%. Its return on capital employed (ROCE) is -58.30%.
Is GDTC a good stock to buy?
This page provides a data-driven analysis of CytoMed Therapeutics Limited (GDTC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.